Introduction
Nephrotoxicity is a major side effect of cisplatin (Arany and Safirstein, 2003) , one of the most effective chemotherapy drugs for cancer (Niedner et al., 2001; Fuertesa et al., 2003; Siddik, 2003) . In the kidneys, renal tubular cells are particularly sensitive to cisplatin injury. Depending on its concentration, cisplatin induces necrosis as well as apoptosis in these cells, leading to acute renal failure. Multiple signaling pathways are activated by cisplatin in renal tubular cells (Baliga et al., 1998; Megyesi et al., 1998; Shiraishi et al., 2000; Kaushal et al., 2001; Nowak, 2002; Park et al., 2002; Ramesh and Reeves, 2002; Liu and Baliga, 2003; Tsuruya et al., 2003; Arany et al., 2004; Li et al., 2004; Sheikh-Hamad et al., 2004; Yu et al., 2005) ; however, it is unclear how these signals are integrated to determine cell injury and death (Arany and Safirstein, 2003) .
Our recent work has examined the involvement of p53 in cisplatin-induced apoptosis of renal tubular cells (Jiang et al., 2004) . Under this condition, apoptosis is suppressed by pifithrin-a, a pharmacological inhibitor of p53. Moreover, cisplatin-induced apoptosis is inhibited by a dominant-negative mutant of p53 (Jiang et al., 2004) . Together with earlier observations (Cummings and Schnellmann, 2002) , these results have suggested a critical role for p53 in cisplatin-induced apoptosis of renal tubular cells. Particularly, the transcriptional activity of p53 seems to be important (Jiang et al., 2004) . Despite these observations, the apoptotic events that are regulated by p53 during cisplatin treatment remain to be determined.
Potential p53-responsive genes include Bcl-2 family proteins (Vousden and Lu, 2002) , which are critical regulators of apoptosis (Adams and Cory, 1998; Danial and Korsmeyer, 2004) . Defined by the presence of Bcl-2 homology (BH) domains, Bcl-2 family proteins can be proapoptotic or antiapoptotic. Specific function of individual Bcl-2 proteins is determined by the presence and organization of the BH domains (Adams and Cory, 1998; Danial and Korsmeyer, 2004; Green and Kroemer, 2004) . In general, antiapoptotic members, like Bcl-2 and Bcl-xL, contain four BH (BH1-4) domains. The proapoptotic members can be further divided into two subclasses, multi-BH domain proteins and BH3-only proteins. Multi-BH domain proteins, including Bax and Bak, contain three BH (BH1-3) domains.
Bcl-2 homology 3-only proteins have only one BH (BH3) domain, which include Bid, Bad and many others (Adams and Cory, 1998; Danial and Korsmeyer, 2004; Green and Kroemer, 2004) . In Bcl-2 family proteins, Bax is the first to be shown to be transcriptionally regulated by p53 (Miyashita and Reed, 1995) . More recently, studies have further suggested Bax activation by p53 in a transcription-independent manner (Chipuk et al., 2004) . Transcriptional activation of Bid by p53 has also been documented (Sax et al., 2002) . Importantly, PUMA, a newly identified BH3-only protein, is induced by p53 (Nakano and Vousden, 2001; Yu et al., 2001) and has been implicated in p53-mediated apoptosis by in vitro as well as in vivo gene knockout studies (Jeffers et al., 2003; Yu et al., 2003) .
PUMA is initially identified as a novel BH3-only protein (Nakano and Vousden, 2001; Yu et al., 2001) . Expression of PUMA triggers rapid apoptosis in colorectal cancer cells. Importantly, suppression of PUMA expression attenuates p53-mediated apoptosis (Jeffers et al., 2003; Villunger et al., 2003; Yu et al., 2003) . Further studies have identified several isoforms of PUMA, including PUMA-a, -b, -g and -d (Nakano and Vousden, 2001) . Noticeably, these isoforms may not be subjected to the same regulation, suggesting diverse functions of the proteins (Nakano and Vousden, 2001) .
The current study has examined the regulation of Bcl-2 family proteins during the development of cisplatininduced renal cell apoptosis. We show that Bcl-xL expression is suppressed during cisplatin treatment, while Bak is slightly increased. PUMA-a demonstrates a drastic induction, concomitant with the development of apoptosis. Importantly, PUMA-a induction is attenuated by dominant-negative p53 and pifithrin-a, a pharmacological p53 inhibitor. This is accompanied by the suppression of apoptosis. Moreover, cisplatininduced apoptosis is ameliorated in PUMA knockout cells. In vivo, PUMA-a is induced during cisplatin nephrotoxicity, and, importantly, the induction is abrogated in p53-deficient animals. Together, the results suggest a role for PUMA-a in p53-mediated renal cell apoptosis during cisplatin nephrotoxicity.
Results
Expression of Bcl-2 family proteins following cisplatin treatment To determine the changes in Bcl-2 family proteins following cisplatin treatment, our initial experiments examined the levels of their expression. Cells, after 24 h of incubation with or without 20 mM cisplatin, were lysed in SDS buffer to collect whole-cell lysates for immunoblot analysis. The results are shown in Figure 1 . Following cisplatin treatment, the expression of Bcl-xL, an antiapoptotic protein, decreased markedly. In contrast, the proapoptotic protein Bak showed a marginal and yet reproducible increase, while no obvious changes were shown in the expression of Bax and Bid (Figure 1a) . The most noticeable changes were shown in PUMA-a (Figure 1b) , a newly identified BH3-only protein that was shown to be p53 responsive (Nakano and Vousden, 2001; Yu et al., 2001 ). PUMA-a was drastically induced in cisplatin-treated cells and the induction appeared specific, since no induction was shown for PUMA-b or -g (Figure 1b ). Together, the results showed that cisplatin treatment induced specific alterations in the expression of Bcl-xL, Bak and PUMA-a.
Temporal relationship between apoptosis development, p53 activation and Bcl-2 family protein expression during cisplatin treatment Our previous work suggested a role for p53 in cisplatininduced renal cell apoptosis (Jiang et al., 2004) . To gain information on the relationship between p53 activation, Bcl-2 family protein expression and apoptosis, we determined the time courses of their occurrence. As shown in Figure 2a , no significant apoptosis was detected during the first 4 h of cisplatin incubation. By the end of 8 h apoptotic cells were detected, but the amount was usually under 5%. Following the initial 8 h of cisplatin treatment, apoptosis escalated. The cells showed typical morphology of apoptosis, including cellular shrinkage, formation of apoptotic bodies, nuclear condensation and fragmentation (morphology not shown; see Jiang et al., 2004) . After 16 and 24 h of cisplatin incubation, about 35 and 70% apoptosis were detected, respectively (Figure 2a ). To further characterize and quantify apoptosis, we measured caspase activity and demonstrated a time-dependent activation of caspases (Figure 2b) , and, again, drastic increases of caspase activity were shown after 16-24 h of cisplatin incubation (Figure 2b ). We then collected whole-cell lysates at different time points of cisplatin treatment to analyse p53 and Bcl-2 family proteins by immunoblotting. As shown in Figure 2c , p53 activation, indicated by its induction and phosphorylation, was detected following 4 h of cisplatin treatment, and continued thereafter. Bcl-xL increased during the first 4 h of cisplatin treatment, followed by progressive decreases toward PUMA-a in cisplatin-induced renal cell apoptosis M Jiang et al basal levels (Figure 2c ). Of note, under control conditions without cisplatin exposure, Bcl-xL expression increased continuously during the course of 24 h of cell culture (data not shown). Thus, the cessation of Bcl-xL expression after >4 h of cisplatin treatment was consistent with the results shown in Figure 1 , suggesting that Bcl-xL expression was suppressed during cisplatin incubation. Bak expression did not change during the first 4-8 h of cisplatin treatment, and then showed a marginal increase after 16 and 24 h of treatment (Figure 2c ). PUMA-a did not change during the first 4 h, but was markedly induced after 8 h of cisplatin treatment; thereafter, PUMA-a expression was sustained at high levels ( Figure 2c) . As a control, the expression of b-actin did not change significantly during cisplatin treatment (Figure 2c ). Overall, with the antiapoptotic Bcl-xL decreased and the proapoptotic Bak and PUMA-a increased, the changes of these Bcl-2 family proteins were consistent with their involvements in cisplatin-induced tubular cell apoptosis. Importantly, p53 activation preceded PUMA-a induction, which seemed to coincide with the initiation and progression of apoptosis.
Bax activation and cytochrome c release during cisplatin treatment The changes in the expression of Bcl-xL, Bak and PUMA-a (Figures 1 and 2 ) suggested their involvements in cisplatin-induced apoptosis. As critical regulators of apoptosis, Bcl-2 family proteins control apoptosis mainly through their regulation of mitochondrial integrity (Adams and Cory, 1998; Martinou and Green, 2001; Danial and Korsmeyer, 2004) . In this regard, Bax translocates to mitochondria and induces the release of apoptogenic proteins such as cytochrome c (Adams and Cory, 1998; Danial and Korsmeyer, 2004) . With these considerations, we determined Bax translocation during cisplatin-induced apoptosis. As shown in Figure 3a , in control cells, the majority of Bax was shown in the cytosolic fraction (lane 1, cytosol). Bax translocation to the organellar fraction (containing mitochondria) was not evident during the first 8 h of cisplatin treatment (lane 2, organelle). By the end of 16-24 h, significantly more Bax appeared in the organellar fraction (lanes 3 and 4, organelle); this was accompanied by the loss of Bax from the cytosolic fraction (lanes 3 and 4, cytosol). Notably, Bax translocation was accompanied by cytochrome c release from mitochondria. As shown in . By the end of 24 h, the majority of cytochrome c was released into the cytosol (lane 8). These results, consistent with earlier observations (Park et al., 2002) , suggested a role for the mitochondrial pathway of apoptosis in cisplatin-induced renal cell injury. Importantly, the alterations in Bcl-xL, Bak and PUMA-a expression paralleled or preceded Bax activation and cytochrome c release.
PUMA-a accumulation in mitochondria and interaction with Bcl-xL in cisplatin-treated cells The induction of PUMA-a in our experimental model was of particular interest, because this protein was previously shown to activate Bax and initiate apoptosis in colorectal cancer cells . In our experiments, PUMA-a induction preceded Bax activation, cytochrome c release and apoptosis (Figures 2 and 3). A critical event of PUMA-a cytotoxicity in colorectal cancer cells is the accumulation of PUMA-a in mitochondria, where it may activate Bax and trigger the release of apoptogenic factors, including cytochrome c . To determine the subcellular localization of PUMA-a under our experimental condition, we isolated mitochondria for immunoblot analysis. The results are shown in Figure 4a . Regardless of whether or not the cells were treated with cisplatin, PUMA-a was detected in the mitochondrial fraction (lanes 3 and 4, PUMA-a). Consistent with its induction by cisplatin, significantly more PUMA-a was shown in the mitochondria of cisplatin-treated cells (lane 4). In contrast to PUMA-a, PUMA-g was shown mainly in the cytosolic fraction (lanes 1 and 2). As a control, the blots were reprobed for COX IV, an integral mitochondrial protein. As expected, COX IV was detected in the mitochondrial fraction ( Figure 4a ). Due to the lack of suitable antibodies, we were unable to further confirm the mitochondrial localization of PUMA-a by immunofluorescence. Nevertheless, the immunoblot results strongly suggested that cisplatin induced PUMA-a in mitochondria, consistent with a role of this protein in mitochondrial permeabilization and subsequent apoptosis. We hypothesized that, upon induction in mitochondria, PUMA-a may promote cell death by antagonizing the antiapoptotic proteins, including Bcl-2 and Bcl-xL, via molecular interaction. In the renal tubular cells used in our study, Bcl-xL was expressed at significantly higher levels than Bcl-2 . Thus, we determined the interaction between PUMA-a and Bcl-xL by co-immunoprecipitation. Whole-cell lysates were extracted from control and cisplatin-treated cells, and precipitated with a monoclonal antibody to Bcl-xL. The precipitates were analysed for the presence of PUMA-a by immunoblotting. As shown in Figure 4b , PUMA-a was detected in Bcl-xL immunoprecipitates. Importantly, more PUMA-a was co-precipitated with Bcl-xL in cisplatin-treated cells (lane 6), suggesting an increased interaction between these two molecules under the injury condition. The blot was reprobed for Bcl-xL ( Figure 4b , lower blot). Consistent with earlier results (Figure 1 ), less Bcl-xL was shown in cisplatin-treated cell lysates (lane 6). Altogether, this experiment suggested that, upon induction, PUMA-a might antagonize Bcl-xL via molecular interaction to promote tubular cell apoptosis during cisplatin treatment.
Inhibition of PUMA-a expression by pifithrin-a during cisplatin treatment To further gain insights into the regulation of Bcl-xL, Bak and PUMA-a during cisplatin treatment, we examined the effects of pifithrin-a, a pharmacological p53 inhibitor (Komarov et al. 1999) , and carbobenzoxyVal-Ala-Asp-fluoromethyl ketone (VAD), a peptide inhibitor of caspases. Representative blots and the results of densitometric analysis are shown in Figure 5 . Consistent with earlier results (Figure 1) , cisplatin suppressed the expression of Bcl-xL, and, importantly, the suppression was not abrogated by pifithrin-a or VAD (Figure 5a and b) . Bak induction by cisplatin was slightly lower in the presence of these inhibitors; nevertheless, the effects were not statistically significant (Figure 5a and c) . On the contrary, PUMA-a induction during cisplatin treatment was attenuated by pifithrin-a, while VAD had no effect (Figure 5a and d) . Consistent with our previous report (Jiang et al., 2004) , pifithrin-a and not VAD inhibited p53 activation during cisplatin treatment (Figure 5a ). Nevertheless, both pifithrin-a and Figure 4 PUMA-a accumulation in mitochondria and interaction with Bcl-xL following cisplatin treatment. (a) PUMA-a accumulation in mitochondria. Rat kidney proximal tubular cells were incubated for 24 h in the absence (À) or presence ( þ ) of 20 mM cisplatin. After incubation, the cells were fractionated into cytosolic and mitochondrial fractions as described in Materials and methods. The fractions were analysed for PUMA by immunoblot analysis. The blots were also reprobed for COX IV to monitor the fractionation procedure. The results suggest that PUMA-a was specifically induced in mitochondria, while PUMA-g was mainly in the cytosol. (b) Co-immunoprecipitation of PUMA-a with Bcl-xL. Control-and cisplatin-treated cells were extracted with CHAPS to collect lysates for immunoprecipitation with a monoclonal antibody to Bcl-xL. The resultant immunoprecipitates were analysed for the presence of PUMA-a by immunoblotting. The blot was reprobed for Bcl-xL. The results show that PUMA-a coimmunoprecipitated with Bcl-xL, suggesting an interaction between these two molecules. More PUMA-a was precipitated from the lysates of cisplatin-treated cells, consistent with PUMA-a induction and enhanced interaction with Bcl-xL.
PUMA-a in cisplatin-induced renal cell apoptosis M Jiang et al VAD suppressed apoptosis in this experimental model (Figure 5e and f). In a separate experiment, we demonstrated that PUMA-a was induced in Bcl-2-overexpressing cells, which did not undergo apoptosis during cisplatin treatment (data not shown). Together, the results indicated that PUMA-a induction following cisplatin treatment was not a consequence of cell death or apoptosis. The observation that pifithrin-a ameliorated p53 activation, PUMA-a induction and apoptosis suggested that p53 and PUMA-a might be involved in the initiation and progression of apoptosis during cisplatin treatment.
Effects of pifithrin-a on Bax translocation and cytochrome c release during cisplatin treatment During cisplatin treatment, PUMA-a was induced in mitochondria and interacted with Bcl-xL (Figure 4) . It was hypothesized that, by antagonizing Bcl-xL, PUMA-a might activate the mitochondrial pathway of apoptosis. To test this possibility, we compared Bax activation and cytochrome c release during cisplatin treatment in the absence or presence of pifithrin-a, which, as shown in Figure 5 , was able to attenuate PUMA-a induction. The results are shown in Figure 6 . Consistent with earlier results (Figure 3) , cisplatin treatment led to Bax accumulation Similarly, pifithrin-a suppressed cytochrome c release during cisplatin incubation. As shown in Figure 6b , cisplatin treatment released cytochrome c into the cytosol (lane 5), which was largely prevented by pifithrin-a (lane 6). These observations suggested that, as a result of p53 inhibition, pifithrin-a may ameliorate PUMA-a induction and abrogate the mitochondrial pathway of apoptosis.
Effects of dominant-negative p53 on PUMA-a induction and apoptosis during cisplatin treatment To extend the pharmacological observations with pifithrin-a ( Figures 5 and 6) , we stably expressed a dominantnegative mutant of p53 (DN-p53) in rat kidney proximal tubular cell line (RPTC) cells to specifically inhibit p53. We tested three DN-p53 cell clones. As shown in Figure 7a , PUMA-a was induced by cisplatin in these clones (lanes 4, 6 and 8), but the induction was lower than that of wild-type RPTC cells (lane 2). The conclusion was further supported by the results of densitometric analysis (Figure 7b) . Importantly, the suppression of PUMA-a induction by DN-p53 was accompanied by the amelioration of apoptosis and caspase activation (Figure 7c and d) . These observations, together with the pifithrin-a results, suggested an important role for p53 in PUMA-a induction during cisplatin incubation.
PUMA-a induction in vivo during cisplatin nephrotoxicity and its inhibition by p53 deficiency To extend the in vitro findings to in vivo situations, we examined PUMA-a induction in a characterized model of cisplatin nephrotoxicity (Megyesi et al., 1998; Ramesh and Reeves, 2002) . In C57 mice, one dose of cisplatin induced acute renal failure within a few days (data not shown; Wei et al., 2005) . Renal tissues were collected to determine PUMA-a by immunoblot analysis. As shown in Figure 8 , PUMA-a expression in kidneys of saline-injected control animals was very low (lane 1). Following cisplatin injection, PUMA-a was drastically induced (lanes 2 and 3). Importantly, the inductive response was abrogated in p53-deficient animals (lanes 4 and 5). The same blots were reprobed for p53, showing p53 induction by cisplatin in wild-type (lanes 2 and 3) but not in p53-deficient (lanes 4, 5) animals. The in vivo results demonstrated PUMA-a induction during cisplatin nephrotoxicity and, importantly, p53-dependence of the induction. 
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Suppression of cisplatin-induced apoptosis in PUMA knockout cells
The results presented above suggested the possible involvement of PUMA-a in cisplatin-induced apoptosis. To directly test this possibility, we compared wild-type (PUMA þ / þ ) and PUMA knockout (PUMA À/À ) cells. HCT116 cells with targeted PUMA gene deletion were described previously . By morphology, apoptotic cells were not identified in control HCT116 cells, regardless of the presence or absence of PUMA (Figure 9a ). When the cells were subjected to cisplatin incubation for 24 h, over 50% PUMA þ / þ cells underwent apoptosis, developing typical apoptotic morphology. In contrast, less than 20% apoptosis was induced by cisplatin in PUMA À/À cells (Figure 9a ). To confirm the morphological observations, we measured caspase activity. As shown in Figure 9b , in PUMA þ / þ cells, caspase activity increased to B11 nmol/mg/h following cisplatin treatment, while the caspase activity in PUMA À/À cells was B4 nmol/mg/h.
Discussion
This study has examined the expression and regulation of several critical Bcl-2 family proteins during the development of cisplatin-induced apoptosis. Changes are identified in the expression of Bcl-xL, Bak and PUMA-a. Expression of Bcl-xL, a known antiapoptotic gene, is suppressed by cisplatin, whereas the proapoptotic Bak and PUMA-a are induced. Thus, overall, the changes are expected to favor the initiation of apoptosis. Importantly, PUMA-a induction is drastic and is accompanied by the progression of apoptosis. The inductive response is abrogated by DN-p53 and pifithrin-a, suggesting a role of p53 in PUMA-a induction. Noticeably, under these conditions, apoptosis is attenuated. In vivo, PUMA-a is induced by cisplatin in wild-type but not p53-deficient animals. The involvement of PUMA-a in cisplatin injury is further supported by the observation that apoptosis was ameliorated in PUMA knockout cells. Together, these findings have demonstrated compelling evidence for the involvement of p53/PUMA-a in cisplatin nephrotoxicity.
Bcl-xL appears to be an important regulator of apoptosis in the renal tubular cells that are used in this study. Compared with Bcl-2, the expression level of Bcl-xL is much higher in these cells Wang et al., 2004) . Bcl-xL is localized not only in mitochondria but also in the cytosol , suggesting that it may regulate apoptosis at both sites and probably through multiple mechanisms. Interestingly, our recent work has shown that deathresistant cells selected by repeated episodes of hypoxic stress upregulate Bcl-xL, which appears to play a pivotal role in the death resistance of these cells ). In the current study, Bcl-xL increases during cell culture under control conditions. With cisplatin, the culture-associated Bcl-xL expression is diminished. Similar observations have been documented in cancerous cells (Nagane et al., 1998; Akeshima et al., 2001) . Although the mechanism underlying the suppression is unknown, it may be related to changes in cell cycle. Cell cycle arrest and apoptosis have been shown to occur concurrently in various types of cells, and in several recent studies decreases of Bcl-xL have been demonstrated under such conditions (Chang et al., 2005; Shen et al., 2005) . In the current study, we have examined the potential regulation of Bcl-xL by p53. It is shown that pifithrin-a, a pharmacological inhibitor of p53, does not prevent Bcl-xL decreases during cisplatin treatment, suggesting that p53 is not a major Figure 8 PUMA-a induction in vivo during cisplatin nephrotoxicity and its inhibition by p53-deficiency. Wild-type (p53 þ / þ ) and p53-deficient (p53 À/À ) mice were injected with cisplatin. Renal tissues were collected 3 days later for immunoblot analysis of PUMA-a and p53. b-Actin was also analysed as a control of sample loading. The results show that cisplatin induced PUMA-a in wild-type animals, but not in p53-deficient mice. PUMA-a in cisplatin-induced renal cell apoptosis M Jiang et al player in the regulation. Regardless of its underlying mechanism, suppression of Bcl-xL by cisplatin is expected to sensitize the cells to apoptosis. Among the three Bcl-2 family proteins that change expression following cisplatin treatment, PUMA-a shows the best correlation with the development of apoptosis. PUMA-a induction is drastic, while Bak induction is obviously at a lower level. Importantly, PUMA-a is induced during the initiation period (B8 h of cisplatin incubation) of apoptosis, and the induction persists during the progression/development phase of apoptosis. On the contrary, Bak induction is not detected until the late stage of massive apoptosis (16-24 h of cisplatin incubation). The role played by PUMA-a in tubular cell apoptosis in our experimental model is further strengthened by the experiments using pifithrin-a. Pifithrin-a suppresses PUMA-a induction, but not Bcl-xL decrease or Bak increase ( Figure 5 ). Under this condition, Bax activation, cytochrome c release as well as apoptosis are attenuated (Figure 6 ), suggesting that PUMA-a, and not Bcl-xL or Bak, plays a critical role in triggering the apoptotic cascade. The conclusion is further supported by the study of PUMA knockout cells, demonstrating the amelioration of cisplatin-induced apoptosis as well as caspase activation (Figure 9 ).
Despite strong evidence for a role of PUMA-a in cisplatin-induced apoptosis, it is less clear as to how PUMA-a initiates apoptosis under the conditions. Nevertheless, the current study shows that PUMA-a is induced in mitochondria (Figure 4a ) and, importantly, in mitochondria it may be interacting with other Bcl-2 family proteins such as Bcl-xL (Figure 4b ). These observations suggest that PUMA-a may promote apoptosis by regulating the integrity of mitochondria. Specifically, it may antagonize the antiapoptotic molecules (e.g. Bcl-xL) via molecular binding and neutralization. The molecular interactions between Bcl-2 family proteins have been recognized for years (Adams and Cory, 1998; Danial and Korsmeyer, 2004) . However, the specificity of the interactions and the functional consequences remain unclear. Recent studies from Korsmeyer's laboratory demonstrated that cells lacking multi-BH domain proteins (i.e. Bax and Bak) became resistant to injury induced by BH3-only proteins . They further showed that Bcl-2 sequestered BH3-only proteins to prevent apoptosis . We demonstrated recently that transfection of the BH3-only protein Bid activated Bax and Bak to permeabilize mitochondria, leading to apoptosis. Cotransfection of Bcl-2 blocked Bid insertion into mitochondria, which was accompanied by the suppression of Bax/Bak activation, mitochondrial damage and cell death (Yi et al., 2003) . Together, these findings have suggested a model of functional interactions between Bcl-2 family proteins. In this model, BH3-only proteins act upstream of multi-BH domain proteins, including Bax and Bak. Upon activation, Bax and Bak oligomerize to form porous defects in mitochondria, resulting in lethal damage. Death-inhibitory proteins such as Bcl-2 and Bcl-xL block cell death mainly by sequestering BH3-only proteins. In the current study, Bax activation followed by cytochrome c release is demonstrated during cisplatin treatment (Figure 3) . Importantly, these mitochondrial events of apoptosis are abrogated, when PUMA-a induction is suppressed (Figure 6 ). The results suggest that PUMA-a may provide a critical upstream signal for Bax activation under the experimental condition. According to the functional interaction model, PUMA-a as a BH3-only protein may directly activate Bax or indirectly, through the binding/neutralization of antiapoptotic proteins. Our results have demonstrated the binding of PUMA-a with Bcl-xL, supporting the latter scenario. With Bcl-xL being neutralized by PUMA-a, Bax becomes free to permeabilize the mitochondrial membrane. Alternatively, other proapoptotic proteins (e.g. p53; Chipuk et al., 2005) are released from Bcl-xL to activate Bax.
p53 has been implicated in the regulation of PUMA-a during genotoxic stress (Nakano and Vousden, 2001; Yu et al., 2001; Jeffers et al., 2003; Villunger et al., 2003) . Indeed, a p53-binding site is identified in the puma gene (Nakano and Vousden, 2001) . Consistently, our results from both in vitro and in vivo experiments have suggested a critical role for p53 in PUMA-a induction during cisplatin nephrotoxicity. In in vitro experiments, we show that pifithrin-a, the pharmacological inhibitor of p53, suppresses PUMA-a induction (Figure 5a, d) . Moreover, PUMA-a induction is suppressed by a dominant-negative mutant of p53 (Figure 7 ). Of note, the DN-p53 has a specific point mutation at the transactivation site, which attenuates its transcriptional activity. Thus, most likely, the dominant-negative mutant inhibits p53-mediated PUMA transcription during cisplatin treatment. In in vivo experiments, we demonstrate PUMA-a induction in the kidneys following cisplatin nephrotoxicity. Importantly, the induction is abrogated in p53-deficient animals ( Figure 8 ). While these observations extend previous findings of p53/PUMA-a regulation under genotoxic stress, they may bear significant implications in our understanding of cisplatin nephrotoxicity, an important clinical condition. In line with the thinking, our preliminary results suggest that p53-deficient mice may be resistant to cisplatin-induced acute kidney injury (Wei and Dong, unpublished preliminary results) .
Therapeutically, our findings suggest the possibility of renal protection by blocking p53/PUMA-a during cisplatin treatment. Nevertheless, it is undesirable to limit p53/PUMA-mediated killing of cancer cells. In this aspect, it is important to recognize that over 50% of cancers have p53 mutations; yet cisplatin is frequently effective in treating them, indicating that cisplatin therapy in cancer cells may not stringently depend on wild-type p53 or PUMA-a (Siddik, 2003; Gudkov and Komarova, 2005) . During the treatment of these cancers, protection of kidneys by targeting p53/PUMA is not expected to diminish the therapeutic effects of cisplatin, because the killing of cancer cells by cisplatin under these conditions is most likely p53-independent. In addition, approaches of targeted kidney delivery, including gene therapy, are being developed (Tomasoni and Benigni, 2004) . Renal tissues by their enormous reabsorption capacity are particularly accessible to drugs, including antisense oligonucleotides and siRNA (Tomita et al., 2004) . As a result, chemoprotective strategies may be developed to specifically target p53/ PUMA-a in the kidneys.
In addition to PUMA, several other Bcl-2 family proteins have been shown to be induced or regulated by p53. These include Bax, Noxa and Bid (Miyashita and Reed, 1995; Oda et al., 2000; Sax et al., 2002) . All gene promoters of these proteins all contain p53-binding sites. However, surprisingly, induction of these proteins seems to be quite specific; thus far, there is no report showing simultaneous induction of all the four. In the current study, PUMA-a is induced, but neither Bax nor Bid show evident induction (Figure 1) . Therefore, despite the presence of p53-binding elements, regulation of these genes by p53 is stimulation and cellular context specific. Most likely, the binding of p53 and subsequent initiation of gene transcription are subjected to complex regulations by coactivators and repressors.
In conclusion, this study has examined Bcl-2 family protein expression and regulation during cisplatininduced tubular cell apoptosis. While Bcl-xL expression is suppressed by cisplatin, Bak and PUMA-a are induced. PUMA-a induction is drastic and p53-dependent. Following induction, PUMA-a accumulates in mitochondria, where it may interact with and antagonize Bcl-xL. As a result, Bax is activated to permeabilize the mitochondrial membrane and release cytochrome c, leading to apoptosis (Figure 10 ).
Materials and methods
Materials
The RPTC was originally obtained from Dr U Hopfer (Case Western Reserve University, Cleveland, OH) and maintained for experiments as described (Woost et al., 1996) . Rat kidney proximal tubular cells stably transfected with dominantnegative p53 were generated as described in our previous work (Jiang et al., 2004) . PUMA knockout HCT116 cells were generated by targeted gene deletion .
Antibodies used in this study were from the following sources: monoclonal anti-Bcl-xL (clone 4) from BD Pharmingen (San Diego, CA, USA); monoclonal anti-Bax (1D1) and anti-Bcl-xL (2H12) from NeoMarkers (Fremont, CA, USA); polyclonal anti-Bak (NT) from Upstate Biotechnology; monoclonal anti-COX IV (20E8) from Molecular Probes (Eugene, OR, USA); rabbit polyclonal anti-p53 and anti-phospho-p53 (Ser15) antibodies from Cell Signaling Technology (Beverly, MA, USA) and from BD Pharmingen (San Diego, CA, USA). Polyclonal anti-Bid was from Dr Xiao-Ming Yin at the Department of Pathology, University of Pittsburgh; polyclonal anti-PUMA was generated as described previously (Yu et al., 2001) ; all secondary antibodies were from Jackson ImmunoResearch (West Grove, PA, USA). Carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone was purchased from Enzyme Systems Products (Dublin, CA, USA). Other reagents, including cisplatin and pifithrin-a, were from Sigma Chemical Co. (St Louis, MO, USA).
In vitro model of cisplatin injury Rat kidney proximal tubular cells were treated with cisplatin as described in our recent study (Jiang et al., 2004) . Briefly, cells were plated to reach B90% confluence by the next day. For experiments, cisplatin stock of 100 mM was freshly prepared in DMSO and added to cells at a final concentration of 20 mM. At the end of incubation, cells were monitored morphologically or lysed with indicated buffers to collect cell lysate for biochemical analyses. For cell lysis, both floating and adherent cells were collected. For HCT 116 cells, 50 mM cisplatin was added to induce apoptosis.
In vivo model of cisplatin nephrotoxicity Wild-type and p53-deficient C57 mice (male, B8 weeks) were injected (intraperitoneal, 30 mg/kg) with one dose of cisplatin. Control animals were injected with saline. Renal injury and renal failure were monitored (not shown). Renal tissues were collected 3 days after cisplatin injection. Whole-tissue lysates were examined by immunoblot analysis.
Morphological examination of apoptosis
Apoptosis was monitored morphologically, as described in our previous studies (Jiang et al., 2004; Wang et al., 2004) . Briefly, cells were exposed to 10 mg/ml of Hoechst 33 342 for 2-5 min to stain the nuclei. Cellular and nuclear morphology was then examined by phase-contrast and fluorescence microscopy. Apoptosis was indicated by cellular shrinkage, nuclear condensation and fragmentation, and the formation of apoptotic bodies. Four fields with B200 cells per field were checked in each dish to estimate the percentage of apoptosis.
Determination of caspase activity Caspase activity was measured by enzymatic assay using the fluorogenic peptide substrate DEVD.AFC, as described previously (Jiang et al., 2004; Wang et al., 2004) . After treatment, cells were extracted with 1% Triton X-100. The lysates were added to enzymatic reactions containing 50 mM DEVD.AFC for 60 min of reaction. The fluorescence at excitation 360 nm/emission 530 nm was monitored by a GENios plate-reader (Tecan US Inc., Research Triangle Park, NC, USA). A standard curve was constructed using free AFC in each measurement. Using the standard curve, the fluorescence reading from each enzymatic reaction was translated into the nanomolar amount of liberated AFC. Caspase activity was expressed as the nanomolar amount of liberated AFC by each mg protein of cell lysate. PUMA-a in cisplatin-induced renal cell apoptosis M Jiang et al
Analysis of PUMA accumulation in mitochondria Mitochondria were isolated by a method modified from a recent study (Li et al., 2004) . Cells were rinsed with ice-cold phosphate-buffer saline and homogenized on ice with a 1-ml Wheaton homogenizer in a buffer containing 150 mM NaCl, 10% sucrose, 20 mM EDTA, 5 mM EGTA, 2 mM DTT, 1 mM PMSF and 30 mM Tris-HCl, pH 7.4. The homogenate was centrifuged at 41C at 1000 g for 5 min to remove nuclei, unbroken cells and big debris. The supernatant was further centrifuged at 41C at 20 000 g for 20 min to collect the supernatant containing cell cytosol and the pellet containing mitochondria. The collected fractions were analysed for PUMA by immunoblotting analysis.
Analysis of Bax and cytochrome c redistribution during cisplatin treatment To analyse the subcellular distributions of Bax and cytochrome c, cells were fractionated into cytosolic and membranebound organellar fractions using low concentrations of digitonin. Digitonin at low concentrations selectively permeabilizes the plasma membrane to release cell cytosol. Using digitonin, we and others have determined subcellular distributions of cytochrome c and various Bcl-2 family proteins (Gottlieb and Granville, 2002; Dong and Wang, 2004; Wang et al., 2004) . The feasibility of this fractionation approach to analyse protein redistribution between cytosol and mitochondria has been verified by previous studies (Gottlieb and Granville, 2002; Dong et al., 2003; Dong and Wang, 2004; Wang et al., 2004) . The fractionation procedure was also monitored in the current study by analysing COX IV, an integral protein of mitochondria. For fractionation, cells were exposed to 0.05% digitonin in an isotonic buffer (in mM: 250 sucrose, 10 Hepes, 10 KCl, 1.5 MgCl 2 , 1 EDTA and 1 EGTA; pH 7.1) for 2 min at room temperature. The soluble fraction was collected as cytosolic extract. The remaining digitonininsoluble part was washed once with isotonic buffer, and then dissolved in a 2% SDS buffer to collect the membranebound organellar fraction. The digitonin-soluble and -insoluble fractions were analysed for Bax and cytochrome c by immunoblotting analysis.
Co-immunoprecipitation of Bcl-xL and PUMA Co-immunoprecipitation was conducted according to our recent work (Yi et al., 2003; Dong and Wang, 2004; Wang et al., 2004) . Briefly, whole-cell lysates were collected with a buffer containing 2% CHAPS. The zwitterionic detergent CHAPS was used for extraction to avoid nonionic detergentinduced association between Bcl-2 family proteins (Hsu and Youle, 1998) . Monoclonal anti-Bcl-xL of 1 mg was then added to 500 mg cell lysates, followed by the incubation with 20 ml agarose protein A/G. Immunoprecipitates were collected by centrifugation and dissolved in 2% SDS sample buffer. The solubilized proteins were subjected to immunoblot analysis to detect the presence of PUMA-a. The blots were reprobed for Bcl-xL.
Immunoblot analysis
Protein concentration was determined using the bicinchoninic acid (BCA) reagent (Pierce Chemical Co., Rockford, IL, USA). Same amounts (usually 25 mg) of protein were loaded in each lane for electrophoresis under reducing condition. The resolved proteins were then electroblotted onto PVDF membranes. The membranes were incubated in 1% BSA and 2% fat-free milk for blocking, and then exposed to the primary antibodies overnight at 41C. After extensive washing and blocking in 5% milk, the blot membranes were incubated with the horseradish-peroxidase-conjugated secondary antibody, and antigens on the blots were revealed using the enhanced chemiluminescence (ECL) kit from Pierce.
Statistics
Data were expressed as means7s.d. (nX3). Statistical analysis was conducted using the GraphPad Prism software. Statistical differences in multiple groups were determined by multiple comparisons with Tukey's post-tests following analysis of variance. Statistical differences between two groups were determined by Student's t-test. Po0.05 was considered significantly different.
